During the last session, Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s traded shares were 1.02 million, with the beta value of the company hitting 1.49. At the end of the trading day, the stock’s price was $11.07, reflecting an intraday loss of -0.54% or -$0.06. The 52-week high for the DNA share is $16.85, that puts it down -52.21 from that peak though still a striking 54.83% gain since the share price plummeted to a 52-week low of $5.00. The company’s market capitalization is $647.95M, and the average intraday trading volume over the past 10 days was 2.12 million shares, and the average trade volume was 1.32 million shares over the past three months.
Ginkgo Bioworks Holdings Inc (DNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.75. DNA has a Sell rating from 2 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Ginkgo Bioworks Holdings Inc (DNA) registered a -0.54% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.54% in intraday trading to $11.07, hitting a weekly high. The stock’s 5-day price performance is -2.55%, and it has moved by 45.85% in 30 days. Based on these gigs, the overall price performance for the year is 12.73%. The short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) is 11.31 million shares and it means that shorts have 10.64 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.5, which implies a decrease of -70.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.35 and $12 respectively. As a result, DNA is trading at a discount of -8.4% off the target high and 60.7% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -27.97%. While earnings are projected to return 41.87% in 2025.
DNA Dividends
Ginkgo Bioworks Holdings Inc is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Ginkgo Bioworks Holdings Inc insiders own 6.88% of total outstanding shares while institutional holders control 79.34%, with the float percentage being 85.20%. VIKING GLOBAL INVESTORS LP is the largest shareholder of the company, while 218.0 institutions own stock in it. As of 2024-06-30, the company held over 143.09 million shares (or 6.9686% of all shares), a total value of $47.83 million in shares.
The next largest institutional holding, with 138.96 million shares, is of VANGUARD GROUP INC’s that is approximately 6.7679% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $46.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ginkgo Bioworks Holdings Inc (DNA) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.31 shares. This amounts to just over 2.84 percent of the company’s overall shares, with a $14.55 million market value. The same data shows that the other fund manager holds slightly less at 637.83, or about 1.38% of the stock, which is worth about $7.06 million.
